NEW YORK, NEW YORK – Nov. 29, 2022 – Deerfield Management Company, a New York City-based healthcare investment firm and Advancium Health Network, a public charity dedicated to advancing healthcare services and health equity through philanthropic investment, announced today the third annual XSeed Award, a program designed to support early-stage life science, minority- and women-led startups in New York City. A change from previous award seasons, this year, two life science startup companies will each be awarded up to $250,000.
“We are excited to continue the XSeed Award program this year, alongside the NYCEDC and our enthusiastic team of board members,” said James E. Flynn, Managing Partner at Deerfield and Cure Founder. “In just our third year, it has already been extremely rewarding to see the program winners progress.”
Finalists will present their work to an esteemed panel that includes: Claire Pomeroy, M.D., President and CEO of the Albert and Mary Lasker Foundation; Elise Wang, Partner at Deerfield; Jenny Laird, VP, Search & Evaluation, Neuroscience at Eli Lilly; Joseph Pearlberg, M.D., Ph.D., Vice President of Scientific Affairs at Deerfield and H.C. Huang, Ph.D., Senior Director, Preclinical Pharmacology, Deerfield Discovery and Development at Deerfield; Nancy Thornberry, Founding CEO at Kallyope.
The deadline for submission is January 16 and virtual finalist presentations will be on March 2, 2023. The winners will be announced on April 3 during the award ceremony at Cure®. To learn more about the XSeed Award’s applicant eligibility criteria and to submit applications, visit www.xseedaward.com.